Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
IMMUNITYBIO DEADLINE FOR LEADERSHIP is May 26, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Via NewMediaWire
Topics Fraud Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
IMMUNITYBIO DEADLINE FOR LEADERSHIP is May 26, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
Via The Motley Fool
Tickers AMGN EVR JEF JNJ REGN SPGI
Exposures Product Safety
News headline image
autoTECH Blackhawk Provides Reliable, Full-Service Car Maintenance in Danville
Via GetFeatured
Topics Economy Product Recall
Tickers F RACE
Exposures Economy Legal Product Safety
News headline image
The Psychedelic Revolution in Mental Healthcare ↗
Via The Motley Fool
Tickers ABBV CMPS
Exposures Product Safety
News headline image
Lifelike Tattoo Studio: Where Ink Becomes Identity in Houston
Via AB Newswire
Topics Product Recall
Exposures Legal Product Safety
News headline image
Bread Loaf’s CEO Mark Milutin Breaks Down FDA Peptide Shift and What It Means for Telehealth
Via AB Newswire
Exposures Product Safety
News headline image
Goldman Sachs' 2 Favorite Under-the-Radar Stocks ↗
Via Benzinga
Tickers GS
Exposures Product Safety
OEM Water Bottle Manufacturing Guide: A Complete Handbook for Brand Owners & Buyers
Via AB Newswire
Exposures Product Safety
News headline image
Deadline to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan Fox
Via TheNewswire.com
Topics Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
Deadline to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan Fox
Via NewMediaWire
Topics Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
AINewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Closes $10 Million Public Offering to Advance Cardiac Technology Commercialization
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Tickers BEAT
Exposures Artificial Intelligence Intellectual Property Product Safety
News headline image
$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior Scientific Advisor for KALA BIO, Inc. (Nasdaq: KALA)
Via Get News
Topics Artificial Intelligence Intellectual Property
Tickers KALA
Exposures Artificial Intelligence Intellectual Property Product Safety
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
Via The Motley Fool
Tickers EXEL JNJ KRYS LLY MDGL UNH
Exposures Product Safety
News headline image
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies ↗
Via The Motley Fool
Topics Stocks
Tickers BAC HIMS
Exposures Product Safety US Equities
News headline image
RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?
Via Barchart.com
Tickers AMZN
Exposures Product Safety
News headline image
IMMUNITYBIO DEADLINE: Investors of ImmunityBio, Inc. (NASDAQ: IBRX) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on May 26, 2026
Via NewMediaWire
Topics Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
IMMUNITYBIO DEADLINE: Investors of ImmunityBio, Inc. (NASDAQ: IBRX) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on May 26, 2026
Via TheNewswire.com
Topics Lawsuit
Tickers IBRX
Exposures Financial Legal Product Safety
News headline image
Hims & Hers Spikes; Will The FDA Blow The Door Open On Peptide Compounding? ↗
Via Investor's Business Daily
Exposures Product Safety
News headline image
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar ↗
Via Benzinga
Tickers LLY
Exposures Product Safety
News headline image
FDA To Review Easing Grip On Several Peptide Therapies Popular Among Influencers And Fitness Gurus In Potential Win For RFK Jr. ↗
Via Benzinga
Exposures Product Safety
News headline image
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Via Newsfile
Tickers CSE:PHRM PHRRF
Exposures Product Safety
News headline image
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
Via Newsfile
Topics Intellectual Property
Tickers OSTX
Exposures Intellectual Property Product Safety
News headline image
Why Is Hims & Hers Stock Soaring After FDA's Announcment? ↗
Via Benzinga
Exposures Product Safety
News headline image
ApiquestUSA Secures Landmark U.S. Patent, Propelling Apivirine to the Forefront of Natural Antiviral Innovation"
Via 24-7 Press Release
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
News headline image
3 Reasons Investors Love DexCom (DXCM)
Via StockStory
Topics Stocks
Tickers DXCM
Exposures Product Safety US Equities
News headline image
Joe Lonsdale Was Once Rejected For A PayPal Internship After An 'Argument' With Max Levchin — Here's How The Palantir Co-Founder Bounced Back ↗
Via Benzinga
Topics Product Recall
Tickers PLTR PYPL
Exposures Legal Product Safety
News headline image
TRAWS PHARMA INC (NASDAQ:TRAW) Reports 2025 Earnings Beat Amid Dilutive $60M PIPE Financing and FDA Hold ↗
Via Chartmill
Topics Earnings
Tickers TRAW
Exposures COVID-19 Financial Product Safety
News headline image
Reglyr Launches AI-Powered Product Compliance Platform Spanning Food, Physical Goods and Cosmetics
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
News headline image
AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
Via PRLog
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.